Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
14: Peptalk Deep Dive — GHK-Cu
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
The copper peptide in half the serums on your shelf. GHK-Cu is a naturally occurring copper peptide your body already makes — levels highest when you're young, declining with age.
This week Jake and Cynthia unpack what it is, what the research actually shows for skin, wound healing, hair, and joints, and why the same molecule gets three different regulatory answers depending on the product.
GLP pulse: Lilly and Hims & Hers strike a direct-sales deal for Zepbound and Foundayo at LillyDirect cash prices — and Hims contractually closes the door on compounded copies of Lilly's GLP-1s.
Retatrutide posts knee osteoarthritis results from two Phase 3 trials in the New England Journal of Medicine. And the Wegovy pill passes 100,000 prescriptions in its first two months — growing the whole GLP-1 pie instead of cannibalizing it.
Deep dive: GHK-Cu's proposed mechanism (collagen and elastin, blood-vessel growth, antioxidant and anti-inflammatory effects), the small human studies behind the skin claims, the 2023 diabetic-mouse wound study, the single small 2013 hair study, and the evidence gap everywhere else.
Plus the safety picture — topicals usually well tolerated, injectables carrying the highest risk — and the FDA's route split: non-injectable compounded GHK-Cu in Category 1 since May 14, 2026 (enforcement policy, not approval), injectable GHK-Cu with its nomination withdrawn and an FDA immunogenicity warning, and GHK-Cu absent from the HHS draft peptide policy's six names.
Next Monday: KPV, the standalone peptide — then the KLOW versus GLOW comparison on November 23, where GHK-Cu returns as one of four.
Everything we discuss is for research and informational purposes only. Not medical advice.
Sources:
- GoodRx, "GHK-Cu for Skin, Hair, and Healing: What Does the Research Show?" by Patricia Pinto-Garcia, MD, MPH, medically reviewed by Sophie Vergnaud, MD, published November 2, 2026 — https://www.goodrx.com/health-topic/peptides/what-is-ghk-cu
- DPS Law, "Is GHK-Cu (Copper Peptide) Legal? 2026 Status," November 2, 2026 — https://dpslaw.com/insights/is-ghk-cu-legal
- U.S. Food and Drug Administration, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act," updated May 14, 2026 — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and
- U.S. Department of Health and Human Services, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," 91 FR 68526 (October 30, 2026)
- Eli Lilly / PR Newswire via Morningstar, "Lilly and Hims & Hers Expand Access to FDA-Approved Lilly Medicines," November 6, 2026 — https://www.morningstar.com/news/pr-newswire/20261106de90839/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines
- Reuters via SRN News, "Lilly to Sell Obesity Drugs Directly on Hims & Hers Site," November 6, 2026 — https://srnnews.com/lilly-to-sell-obesity-drugs-directly-on-hims-hers-site/
- MedicalXpress, "Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials," November 8, 2026 — https://medicalxpress.com/news/2026-11-experimental-weight-loss-drug-eases.html
- Jastreboff et al., "Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity" (TRIUMPH-1), New England Journal of Medicine, 2026; TRIUMPH-4 presented at the American College of Rheumatology annual meeting, Orlando, November 2026
- Healio, "GLP-1 prescriptions for obesity have increased rapidly since introduction of Wegovy pill," November 6, 2026 — https://www.healio.com/news/primary-care/20261106/glp1-prescriptions-for-obesity-have-increased-rapidly-since-introduction-of-wegovy-pill
A Spoke-Media production:
https://www.spoke-media.com